The San Diego biotechnology company is developing the world’s first device-based disease-modifying cell therapy platform to treat debilitating chronic conditions.
Based in San Diego, Paracrine is a clinical (late-stage) biopharmaceutical company that has developed the world’s first autologous, device-based cell therapy platform focused on vascular, immune, and inflammatory conditions. [Paracrine]
Paracrine utilizes an autologous mixed population of adipose-derived regenerative cells that contribute to multiple cell lineages and mechanisms of action to treat complex conditions. This unique heterogeneous cell therapy addresses critical underlying pathologic conditions. The company’s Celution System can process these regenerative cells in about an hour right at the bedside . . .
